12/23/2025
XHANCE Allows a Chronic Rhinosinusitis Patient to Avoid Surgery
Ken Kaltwasser was well on his way to surgery for chronic rhinosinusitis when Martin J. Citardi, MD, professor and chair of the Department of Otorhinolaryngology at McGovern Medical School, suggested a new medical treatment – XHANCE®, which delivers the nasal steroid fluticasone propionate to sinonasal areas not reached by standard-delivery nasal sprays.
https://med.uth.edu/orl/2025/12/01/xhance-allows-a-chronic-rhinosinusitis-patient-to-avoid-surgery/
-FLU